Nektar Therapeutics announces $250M public offering (NKTR:NASDAQ)
Summary
Nektar Therapeutics (NKTR) launches a $250M stock offering with pre-funded warrants to fund R&D and Phase 3 rezpegaldesleukin trials.
Description
Nektar Therapeutics (NKTR) launches a $250M stock offering with pre-funded warrants to fund R&D and Phase 3 rezpegaldesleukin trials.
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source